Inside Trade: Invus Public Equities – L.P. Made a Purchase of 182,838 Shares of Lexicon Pharmaceuticals, Inc. (LXRX); Western Asset Municipal Partners Fund (MNP) Sentiment Is 1.36

July 1, 2018 - By John Hoffman

Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) Logo

Sentiment for Western Asset Municipal Partners Fund Inc (MNP)

Western Asset Municipal Partners Fund Inc (MNP) investors sentiment decreased to 1.36 in 2018 Q1. It’s down -0.08, from 1.44 in 2017Q4. The ratio fall, as 15 funds started new and increased holdings, while 11 sold and decreased their stock positions in Western Asset Municipal Partners Fund Inc. The funds in our database now hold: 1.45 million shares, up from 1.29 million shares in 2017Q4. Also, the number of funds holding Western Asset Municipal Partners Fund Inc in top ten holdings was flat from 0 to 0 for the same number . Sold All: 4 Reduced: 7 Increased: 10 New Position: 5.

Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of pharmaceutical products for the treatment of human diseases. The company has market cap of $1.27 billion. The firm offers XERMELO, an orally-delivered small molecule drug candidate for the treatment of carcinoid syndrome diarrhea in combination with SSA therapy in adults. It currently has negative earnings. The Company’s orally-delivered small molecule drug candidates under development comprise Sotagliflozin that is in Phase 3 clinical trials for use in the treatment of type 1 and type 2 diabetes; LX2761, which is in Phase 1 development for use in the treatment of diabetes; and LX9211 for use as a treatment for neuropathic pain.

More notable recent Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) news were published by: which released: “Lexicon: It’s Show Time At The Roxy” on June 08, 2018, also with their article: “Research Report Identifies Citizens Financial Group, Fifth Third, KKR & Co., Vista Outdoor, Devon Energy, and Lexicon ..” published on June 27, 2018, published: “Lexicon Pharmaceuticals Announces Positive 52-Week Results From Sotagliflozin inTandem1 Study Presented at ADA ..” on June 24, 2018. More interesting news about Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) were released by: and their article: “Lexicon Pharmaceuticals to Present New Clinical Data at 78th American Diabetes Association Scientific Sessions” published on June 18, 2018 as well as‘s news article titled: “Biopharma Companies to Watch This Week” with publication date: June 24, 2018.

Among 6 analysts covering Lexicon Pharmaceuticals (NASDAQ:LXRX), 3 have Buy rating, 2 Sell and 1 Hold. Therefore 50% are positive. Lexicon Pharmaceuticals has $4200 highest and $10.0 lowest target. $25.75’s average target is 114.58% above currents $12 stock price. Lexicon Pharmaceuticals had 10 analyst reports since February 14, 2018 according to SRatingsIntel. As per Monday, May 7, the company rating was maintained by Wedbush. The firm has “Underweight” rating given on Wednesday, February 14 by JP Morgan. Citigroup maintained the shares of LXRX in report on Friday, May 4 with “Buy” rating. J.P. Morgan downgraded Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) on Wednesday, February 14 to “Sell” rating. The rating was maintained by Wedbush with “Buy” on Tuesday, May 22. The company was maintained on Monday, March 12 by Wedbush. The firm earned “Outperform” rating on Monday, April 16 by Wedbush. The stock of Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) earned “Hold” rating by Needham on Friday, February 23. The firm has “Buy” rating by Wedbush given on Monday, June 18. Stifel Nicolaus maintained it with “Buy” rating and $24 target in Friday, May 4 report.

Analysts await Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) to report earnings on August, 7. They expect $-0.35 EPS, down 6.06% or $0.02 from last year’s $-0.33 per share. After $-0.40 actual EPS reported by Lexicon Pharmaceuticals, Inc. for the previous quarter, Wall Street now forecasts -12.50% EPS growth.

An insider of the company Lexicon Pharmaceuticals Inc, Invus Public Equities – L.P., disclosed investment activities with the U.S. SEC on 29/06/2018. As stated in the document, Invus Public Equities – L.P. had purchased 182,838 shares of the public firm. The total insider trading trade was worth $2.29 million USD. At the time of the purchase the price of a share was $12.5. Currently, Invus Public Equities – L.P., holds 35.40 million shares, which accounts for 33.45% of Lexicon Pharmaceuticals Inc’s market capitalization.

The stock decreased 5.81% or $0.74 during the last trading session, reaching $12. About 595,732 shares traded. Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) has declined 34.00% since July 1, 2017 and is downtrending. It has underperformed by 46.57% the S&P500. Some Historical LXRX News: 25/04/2018 – LEXICON RELOCATION BUYS UK-BASED STERLING MOBILITY; 26/03/2018 Lexicon Pharmaceuticals Announces Regulatory Submissions for Sotagliflozin to Treat Adults With Type 1 Diabetes; 04/05/2018 – LEXICON PHARMACEUTICALS REPORTS XERMELO PHASE 3 TELESTAR DATA; 26/03/2018 – Lexicon Pharma: New Drug Application Submitted to U.S. FDA; 29/03/2018 – REG-Sanofi: EMA to review sotagliflozin as potential treatment for type 1 diabetes; 03/05/2018 – LEXICON PHARMA CASH & OTHER $262.3M; 29/03/2018 – Lexicon Pharmaceuticals Announces EMA Acceptance of Marketing Authorization Application (MAA) for Sotagliflozin to Treat Adults With Type 1 Diabetes; 04/05/2018 – Lexicon Pharma Sees Improvements in Diarrhea Severity and Nutritional Status With XERMELO; 22/05/2018 – Sanofi FDA to Review Zynquista(TM) (sotagliflozin) as Potential Treatment for Type 1 Diabetes; 04/05/2018 – LEXICON: PATIENTS ALSO HAD REDUCED U5-HIAA LEVELS

Dixon Hubard Feinour & Brown Inc Va holds 0.06% of its portfolio in Western Asset Municipal Partners Fund Inc. for 14,650 shares. Advisors Asset Management Inc. owns 186,744 shares or 0.04% of their US portfolio. Moreover, Raymond James Trust N.A. has 0.04% invested in the company for 37,871 shares. The New Hampshire-based Charter Trust Co has invested 0.03% in the stock. Landscape Capital Management L.L.C., a New Jersey-based fund reported 20,403 shares.

Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) Ratings Chart